Your browser doesn't support javascript.
loading
ALSUntangled #72: Insulin.
Brown, Andrew; Armon, Carmel; Barkhaus, Paul; Beauchamp, Morgan; Bertorini, Tulio; Bromberg, Mark; Cadavid, Javier Mascias; Carter, Gregory T; Crayle, Jesse; Feldman, Eva L; Heiman-Patterson, Terry; Jhooty, Sartaj; Linares, Alexandra; Li, Xiaoyan; Mallon, Elise; Mcdermott, Christopher; Mushannen, Tasnim; Nathaniel, George; Pattee, Gary; Pierce, Kaitlyn; Ratner, Dylan; Slactova, Lenka; Wicks, Paul; Bedlack, Richard.
Afiliación
  • Brown A; Department of Neurology, University of Miami, Miami, FL, USA.
  • Armon C; Department of Neurology, Loma Linda University Health, Loma Linda, CA, USA.
  • Barkhaus P; Department of Neurology, Medical College of Wisconsin, Milwaukee, WI, USA.
  • Beauchamp M; UNC Health, UNC, Chapel Hill, NC, USA.
  • Bertorini T; Neurology Department, University of Tennessee Health Science Center, Memphis, TN, USA.
  • Bromberg M; Department of Neurology, University of Utah, Salt Lake City, UT, USA.
  • Cadavid JM; ALS Department, Hospital Carlos III-La Paz, Madrid, Spain.
  • Carter GT; Department of Rehabilitation, Elson S. Floyd College of Medicine, Washington State University, Spokane, WA, USA.
  • Crayle J; Department of Neurology, St. Louis, MO, USA.
  • Feldman EL; Department of Neurology, University of Michigan, Ann Arbor, MI, USA.
  • Heiman-Patterson T; Department of Neurology, Temple Health, Philadelphia, PA, USA.
  • Jhooty S; University of North Carolina at Chapel Hill, Chapel Hill, NC, USA.
  • Linares A; Medical School, Duke University, Durham, NC, USA.
  • Li X; Department of Neurology, Duke University, Durham, NC, USA.
  • Mallon E; Undergraduate, Duke University, Durham, NC, USA.
  • Mcdermott C; Department of Neuroscience, University of Sheffield, Sheffield, South Yorkshire, UK.
  • Mushannen T; Department of Neurology, Duke University, Durham, NC, USA.
  • Nathaniel G; Undergraduate, Duke University, Durham, NC, USA.
  • Pattee G; Department of Neurology, University of Nebraska Medical Center, Omaha, NE, USA.
  • Pierce K; Department of Neuroscience, University of North Carolina, Chapel Hill, NC, USA.
  • Ratner D; Undergraduate, Tulane University, New Orleans, LA, USA.
  • Slactova L; Institute of Biology and Medical Genetics, Charles University, Prague, Czech Republic, and.
  • Wicks P; Independent Consultant, Lichfield, England, UK.
  • Bedlack R; Department of Neurology, Duke University, Durham, NC, USA.
Amyotroph Lateral Scler Frontotemporal Degener ; 25(3-4): 416-419, 2024 May.
Article en En | MEDLINE | ID: mdl-38018119
ABSTRACT
ALSUntangled reviews alternative and off-label treatments for people living with amyotrophic lateral sclerosis (PALS). Here we review insulin, which has at least one plausible mechanism for slowing ALS progression. However, pre-clinical studies are limited and there have been no trials in PALS yet. Insulin use in patients without a metabolic need may cause very serious and potentially lethal side effects. While further studies to evaluate potential benefits may be warranted, at this time we cannot endorse insulin treatment to slow ALS progression.
Asunto(s)
Palabras clave
Texto completo
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Bases de datos: MEDLINE Asunto principal: Esclerosis Amiotrófica Lateral Límite: Humans Idioma: En Revista: Amyotroph Lateral Scler Frontotemporal Degener Año: 2024 Tipo del documento: Article País de afiliación: Estados Unidos
Texto completo
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Bases de datos: MEDLINE Asunto principal: Esclerosis Amiotrófica Lateral Límite: Humans Idioma: En Revista: Amyotroph Lateral Scler Frontotemporal Degener Año: 2024 Tipo del documento: Article País de afiliación: Estados Unidos